Search

Displaying results 2721 - 2730 of 4345 in total
  1. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

  2. Drug

    Idarubicin

    go.drugbank.com/drugs/DB01177
    ApprovedInvestigational

    An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

    Products: Idamycin - Cap 10mg, Idamycin Pws 10mg/vial
  3. Drug

    Oportuzumab monatox

    go.drugbank.com/drugs/DB05319
    Investigational

    VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells.

  4. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.

  5. Drug

    Nocodazole

    go.drugbank.com/drugs/DB08313
    Experimental

    Nocodazole is an antineoplastic agent which exerts its effect by depolymerizing microtubules.

  6. Drug

    BCL-005

    go.drugbank.com/drugs/DB17242
    Experimental

    BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells.

  7. Drug

    Piperidione

    go.drugbank.com/drugs/DB13224
    Experimental

    Piperidione was cough medicine marketed by Roche under the trade name Sedulon.

  8. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strateg...

  9. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    It acts by inhibiting viral replication. The use of pleconaril has not gained approval by the U.S. … Pleconaril is an antiviral drug from _viral capsid inhibitor_ class, manufactured by _Schering-Plough_ and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic

  10. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®

    Products: Prolia Solution for Injection 60mg Pre-filled Syringe, Prolia Solution for Injection 60mg/ml Pre-filled Syringe